Stauffer syndrome: a comprehensive review of the disease and diagnostic plan proposal

Sheref A. Elseidy1*, Ahmed K. Awad2, Debvarsha Mandal3, Merihan A. Elbadawy2 and Amir Iqbal4

Abstract

Stauffer syndrome, first described by Herbert Stauffer in 1961, is a hepatic paraneoplastic syndrome characterized by multiple extrahepatic malignancies, most commonly renal cell carcinoma. The syndrome manifests a wide range of symptoms caused by various pathophysiological mechanisms and presents with abnormalities in liver function tests in either cholestatic or non-cholestatic patterns. Stauffer’s syndrome is classified into two types: classical and jaundice variants. Some crossovers continue to occur, complicating the diagnosis of such a rare and frequently missed syndrome, which can be the only diagnostic clue for the retrograde detection of a hidden malignancy.

To bridge the gap regarding such an important, but still unrecognized, syndrome, not only did we thoroughly cover what had previously been proposed in the literature, but we also proposed a diagnostic protocol based on multi-center experience with such a rare disease.

Keywords: Stauffer syndrome, Paraneoplastic, Hepatic dysfunction, Cholestasis, Jaundice, Tyrosine kinase, IL-6

Introduction

Stauffer syndrome is a rare paraneoplastic disorder that affects the liver and is associated with RCC. It is far less common in other malignant neoplasms such as leiomyosarcoma, angiosarcoma, malignant histiocytoma, prostate carcinoma, and bronchial adenocarcinoma [1–4]. Stauffer syndrome is a cholestatic pattern of hepatic dysfunction signs and symptoms with associated abnormalities in liver function tests. This dysfunction is not caused by tumor infiltration of the liver or intrinsic liver disease, but rather by the presence of a paraneoplastic syndrome that causes abnormal bile flow and biliary tract affection through a variety of proposed mechanisms [5]. In cases of idiopathic cholestatic or atypical liver disease, the diagnosis of Stauffer’s syndrome should be considered.

Discussion

Stauffer syndrome is a rare paraneoplastic disorder characterized by hepatic biliary involvement in the presence of visceral malignancy, most commonly renal cell carcinoma. Multiple abnormalities, including hypoalbuminemia, hypergammaglobulinemia, high alkaline phosphatase (ALP), prolonged prothrombin time (PT) without a history of intrinsic liver disease or Hepatic metastasis, and the presence of a concomitant renal cell carcinoma, were observed in the first five initially reported cases. Both liver function tests (LFTs) and clinical signs and symptoms returned to normal following tumor resection [5, 6].

The incidence of the syndrome in patients with RCC varies between 3% and 6%. Although the hepatic dysfunction resolves after primary tumor resection. However, the development of SS in an RCC patient has been associated with a poor prognosis due to deterioration of hepatic functions or due to the advanced stage of the primary tumor when the diagnosis is concealed until the time of diagnosis of that associated paraneoplastic syndrome [7–10].
Pathophysiology
The underlying pathophysiology of this paraneoplastic manifestation has yet to be determined, but three mechanisms have been proposed. The most widely accepted hypothesis proposes a link and a possible role for primary tumor interleukin-6 overexpression [11–13]. Cholestasis and hepatic dysfunction are believed to be secondary to IL-6’s pro-inflammatory activity in Stauffer syndrome. IL-6 increases C-reactive protein and haptoglobin levels and has been shown to inhibit hepatobiliary transporter gene expression. All these factors contribute to biliary outflow impairment [11].

A study found that patients with Stauffer’s syndrome had their biochemical abnormalities reversed after receiving anti-IL-6 monoclonal antibodies. However, such findings did not provide a definitive definition, but a speculative one. Other humoral mediators have been implicated; this was due to the emergence of increased activity of these mediators when the tested rational association between them was made, resulting in hepatic and hematopoietic compromise [11].

The colony-stimulating factor is another proposed mechanism (CSF). Athymic mice were given renal cancer cells extracted from an SS patient. This resulted in hepatic affection and splenomegaly. Furthermore, polysulphones naphthyl urea suramin, a known CSF inhibitor, improved experimental mice [14]. The third and least supported hypothesis proposed an underlying autoimmune etiology in these patients [15].

Clinical features
The classical variant presents with flank mass, loin pain, and hematuria, with an associated cholestatic abnormality in liver function tests such as elevated alkaline phosphatase, erythrocyte sedimentation rate, α-2-globulin, and γ-glutamyl transferase, hypoalbuminemia, thrombocytosis, prolongation of prothrombin time [16–25].

An extremely rare and uncommon jaundice variant with hyperbilirubinemia, hepatosplenomegaly, abnormal coagulation profile, jaundice, choluria, and pruritus has also been reported. Crossovers in patients’ presentations, on the other hand, have been reported.

This crossover is distinguished by mild epigastric and left upper quadrant tenderness, as well as mildly elevated liver function tests (LFT), erythrocyte sedimentation rate (ESR), and C-reactive protein. On abdominal CT, there was a renal mass with normal liver size and no metastasis. Mild pruritus, dark urine, and stool discoloration are also reported by all patients.

The table below summarizes the laboratory findings of most reported cases to highlight the differences between the two variants [25] (Fig. 1).

Diagnosis
Stauffer’s syndrome currently lacks diagnostic criteria but remains a viable diagnosis when underlying renal malignancy is present in the context of cholestatic liver damage.

The first step toward diagnosis should be a baseline liver function test, with particular attention paid to bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase levels (GGT). A cholestatic elevation of LFTs indicates a defective flow of bile from the liver into the duodenum via the bile ducts and the ampulla of Vater. ALT can be elevated in the later stages of severe cholestasis, but the rise in ALP and/or GGT will exceed any rise in ALT [6–8].

The synthetic function of the liver should be assessed using both prothrombin time (PT) and international normalized ratio (INR). Both can be elevated since decreased bile flow reduces fat-soluble vitamin absorption and impairs the liver’s subsequent clotting factor synthesis, raising the PT.

| Clinical/analytical parameters                                      | Stauffer’s syndrome classic description | Stauffer’s syndrome (jaundice) variant description |
|-------------------------------------------------------------------|----------------------------------------|--------------------------------------------------|
| Alkaline phosphatase                                             | High                                   | High                                             |
| γ-Glutamyl transferase                                            | High                                   | High                                             |
| Albumin                                                          | Low                                    | Low                                              |
| Erythrocyte sedimentation rate                                   | High                                   | High                                             |
| α-2-globulin                                                     | High                                   | High                                             |
| Platelets                                                        | High                                   | High; thrombocytopenia described in one case      |
| Prolongation of prothrombin time                                 | Present                                | Present                                          |
| Hepatosplenomegaly                                               | Present                                | Absent/present                                   |
| Hyperbilirubin                                                   | Absent                                 | Present                                          |
| Jaundice                                                         | Absent                                 | Absent/present                                   |
| Urinary hyperpigmentation                                        | Absent                                 | Present                                          |
| Pruritus                                                         | Absent                                 | Present                                          |
| Resolution after resection of primary tumor                      | Yes                                    | Yes                                              |

Fig. 1 Clinical/analytical parameters for Stauffer’s syndrome variants
A complete liver function panel should be performed to rule out any other underlying abnormality causing acute liver damage, and consultation with the gastroenterology team is recommended. Imaging should be used to confirm hepatosplenomegaly and rule out other causes, such as metastatic disease [7, 23].

An initial ultrasound of the biliary tree and liver should reveal no signs of malignancy, common bile duct (CBD), or hepatic duct dilatation.

Magnetic resonance cholangiopancreatography (MRCP) can aid in the detection of underlying CBD stones or other causes of CBD obstruction, which would be useful if a prior cholecystectomy or ultrasound confirmed CBD dilatation/cholelithiasis.

The renal mass is delineated by a contrast CT scan of the abdomen and pelvis and any underlying hepatic, pancreatic or metastatic malignancy will be further evaluated. CT imaging alone is sufficient to rule out other causes of liver derangement. As with any malignancy, complete staging scans are discussed at the multidisciplinary team (MDT) meeting to decide on further management and whether we should be driven by distinctive clinical presentation intensity and or major lab elevations in consideration of one management approach over the other or even palliative versus more invasive intervention [24, 25].

There should be a high clinical suspicion and understanding of the disorder; however, troubling clinical signs and symptoms that may guide the diagnosis of Stauffer syndrome or other distinct diagnoses are suggested in our literature review. We propose a preliminary diagnosis guideline protocol to be validated further by additional trials (Fig. 2). The only major drawback is the unusual nature of the condition and the scarcity of cases documented.

Further clinical studies are encouraged to cover the whole side of such a rare and overlooked syndrome to ensure proper diagnosis and management avoiding its fatal consequences. Renal cell carcinoma in the presence of elevated liver enzymes presenting in either cholestatic or non-cholestatic patterns should prompt the physician to proceed to the next step, which is a more detailed search of the patient’s medical history for an underlying cause. If no underlying cause is discovered after ruling out NASH, alcoholism, and metabolic syndrome. A negative ultrasound, CT, or MRCP can increase the likelihood of Stauffer syndrome.

**Management**

Disease management remains an MDT decision, but it primarily consists of resection of the occult renal tumor, which is the source of the paraneoplastic syndrome, via nephrectomy after preoperative symptomatic care, such as ursodeoxycholic acid, cholestyramine, and avoidance of hepatotoxic medications.

In recent years, there has been a significant shift in the treatment of metastatic RCC associated with Stauffer syndrome. Whereas neoadjuvant cytoreductive nephrectomy has been the standard of care in RCC, recent evidence from the CARMENA and SURTIME trials suggests that upfront nephrectomy may harm some intermediate- and poor-risk metastatic RCC patients [26].
Treatment guidelines recommend starting with a systemic therapy litmus test. For patients with Stauffer's syndrome, the treatment paradigm becomes more complex. Multiple systemic therapies are approved for first-line treatment of RCC, however, all the regimen's target angiogenesis via TKIs. TKIs harbor their own risk of hepatotoxicity, and their use is contraindicated in the setting of hyperbilirubinemia. Immune checkpoint blockade (ICB) represents a novel and feasible treatment option available in the current treatment landscape of metastatic RCC [27–30].

Conclusion
Stauffer syndrome is a reversible paraneoplastic hepatic dysfunction that can occur in conjunction with a variety of tumors but is most associated with RCC. In cases of idiopathic cholestatic or otherwise atypical liver disease, the diagnosis of Stauffer's syndrome, as well as the possibility of an underlying occult malignant tumor, should always be considered. Because the disease can be used to diagnose an occult malignancy, a high level of clinical suspicion is required.

Abbreviations
LFT: Liver function test; RCC: Renal cell carcinoma; IL-6: Interleukin-6; CSF: Colony-stimulating factor; INR: International normalized ratio; PT: Prothrombin time; TKI: Tyrosine kinase inhibitors; CBD: Common Bile duct; NASH: Nonalcoholic steatohepatitis; CT: Computerized tomography; MDT: Multidisciplinary team; ERCP: Endoscopic retrograde cholangiopancreatography; MRCP: Magnetic retrograde cholangiopancreatography.

Acknowledgements
Daad Hassan SharafEldin, MD. for her contribution in reviewing the manuscript and appraisal.

Authors’ contributions
All the authors have shared work in collecting, analyzing, and writing the research paper. AA and SE were major contributors in writing the manuscript, while D.M. and M.E. were major contributors in collecting needed information from different centers. The manuscript did under the supervision of AI. The authors read and approved the final manuscript.

Funding
Not applicable

Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declarations
Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1 Internal Medicine Department, Rochester General Hospital, Rochester, NY, USA. 2 General Surgery Department, Ain-Shams University, Cairo, Egypt. 3 Caribbean Medical University, Chicago, IL, USA. 4 Gastroenterology Department, Wayne State University, Detroit, MI, USA.

Received: 28 February 2022   Accepted: 16 April 2022
Published online: 04 May 2022

References
1. Sharara AI, Panella TJ, Fitz JG (1992) Paraneoplastic hepatopathy is associated with soft tissue sarcoma. Gastroenterology. 103:330–332
2. Karakolios A, Kasapis C, Kallinkidis T, Kalpidis P, Grigorakis N (2003) Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol. 1:480–483
3. Saintigny P, Spano JP, Tcherakian F, Failer MC, Breau JL (2003) Non-metastatic intrahepatic cholestasis associated with bronchial adenocarcinoma. Ann Med Intern (Paris) 154:171–175
4. Kim YH, Park JM, Kang CD, Seo SO, Lee K, Song G (2021) Prostate Cancer Presenting with Pruritus and Cholestasis. Korean J Gastroenterol 78:39–64. https://doi.org/10.4116/kjg.2021.059
5. Karakolios A, Kasapis C, Kallinkidis T, Kalpidis P, Grigoridis N (2003) Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol. 1(6):480–483
6. Bhangoo M, Cheng B, Botta G, Thorson P, Kosty M (2018) Reversible intrahepatic cholestasis in metastatic prostate cancer: an uncommon paraneoplastic syndrome. Mol Clin Oncol. B609–612
7. Fontes-Sousa M, Magalhães H, da Silva FC, Maurício MJ (2018) Stauffer’s syndrome: a comprehensive review and proposed updated diagnostic criteria. Urol Oncol Semin Oncol Investig. 36(7):321–326
8. Stauffer MH (1961) Nephrogenic hepatomegaly. Gastroenterology. 40:691–696
9. Boxer RJ, Waisman J, Lieber MM, Mampaso FM, Skinner DG (1978) Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 119(4):468–471
10. Sharma N, Darr LJ, Darr A, Sadd G (2019) Stauffer Syndrome: a comprehensive review of the icteric variant of the syndrome. Cureus. 11(10):e6032
11. Blay JY, Rossi JF, Wijdenes J et al (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer. 72:424–430
12. McClellan M, Waither M, Johnson B et al (1998) Serum Interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 159(3):718–722
13. Tsukamoto T, Kumamoto Y, Miyato N et al (1992) Interleukin-6 in renal cell carcinoma. J Urol 148(6):1778–1782
14. Chang S, Yu D, Sherwood E, Koslowski J et al (1992) Inhibitory effects of Suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol 47:1147–1150
15. Aigner E, Strassburg CP, Strasser M, Pohlá-Gubó G et al (2009) Transient autoimmune hepatitis induced by a thymoma. Am J Gastroenterol. 104:1332–1334
16. Morla D, Alazemi S, Lichtstein D (July 2006). “Stauffer’s Syndrome Variant with Cholestatic Jaundice a Case Report”. J Gen Intern Med. 21 (7): C11. https://doi.org/10.1111/j.1525-1497.2006.00448.x. PMC 1924715. PMID 16808761
17. Dourakis SP, Sinani C, Dimitriadou E, Hadziyannis SJ (1997) Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol. 9:311–314
18. Giannakos G, Papanicolaou X, Trafalis D, Michaelidis I, Margaritis G, Christofilakis C (2005) Stauffer’s syndrome variant associated with renal cell carcinoma. Int J Urol. 12:757–759
19. Gremida A, Al-Tae A, Alcorn J et al (2017) Hepatic Dysfunction in Renal cell carcinoma: Not What You Think? Dig Dis Sci. 62:2298–2302. https://doi.org/10.1007/s10620-017-4706-8
20. Puga M, Gonzalez-Ballina E, Rivas-Moral L (2015) Stauffer’s syndrome variant as an unusual case of painless jaundice. Clin Gastroenterol Hepatol. 13(9):A25–A26 16
21. Fernández AB, de Ávila AS (2012) Prothrombin complex concentrate (Octaplex) for postsurgical bleeding control in a Stauffer's syndrome. Ann Hematol. 91(8):1325–17
22. Tomadoni A, Garcia C, Marquez M, Ayala JC, Prado F (2010) Stauffer’s Syndrome with jaundice, a paraneoplastic manifestation of renal cell carcinoma: A case report. Arch Esp Urol. 63(2):S4 18
23. Mazokopakis EE, Papadakis KA, Kofiteridis DP (2007) Unusual causes of intrahepatic cholestatic liver disease. World J Gastroenterol. 13(12):1879
24. Dewana SK, Parmar KM, Sharma G, Bansal A, Panwar P, Mavuduru RS (2019) Paraneoplastic hepatic dysfunction with jaundice in a case of primary renal synovial sarcoma: a very rare scenario. Urol Case Rep. 24(December 2018):100841
25. Chavarriaga J, Fakhri N, Cataño J, Villaquiran C, Rodriguez S, Patino G (2020) Stauffer syndrome, clinical implications, and knowledge gaps, does size matter? Case report. BMC Urol 20(1):105. Published 2020 Jul 20. https://doi.org/10.1186/s12894-020-00671
26. Ito K, Takamori H, Akioka T et al (2021) A Case of Stauffer Syndrome-Like Findings Associated with Metastatic Renal Cell Cancer Improved by Molecular Targeted Therapy. Hinyokika kiyō. Acta Urologica Japonica. 67(7):309–312. https://doi.org/10.14989/actauroljap_67_7_309 PMID: 34353011
27. Küronya Z, Kovács E, Lahm E, Géczi L (2014) Stauffer-szindrómában szenvedő beteg sikeres sunitinibkezelése [Successful sunitinib treatment of a patient with Stauffer’s syndrome]. Magy Onkol. 58(3):162–165
28. Zarrabi K, Masic S, Schaefer C, Bartel MJ, Kutzkov A, Zibelman M (2019) Neoadjuvant checkpoint inhibition in renal cell carcinoma associated Stauffer’s syndrome. Urol Case Rep 29:101077. Published 2019 Nov 25. https://doi.org/10.1016/j.eucr.2019.101077
29. Mejean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 379(5):417–427
30. Bex A, Mulders P, Jewett M et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 5(2):164–170

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.